相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Treatment Outcomes in Neuroendocrine Prostate Cancer
Hiroaki Iwamoto et al.
ANTICANCER RESEARCH (2022)
Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study
Hiroaki Iwamoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer
Hiroaki Iwamoto et al.
PROSTATE (2021)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2021)
Efficiency of C-reactive protein in prognosis evaluation of prostate cancer: a systematic review and meta-analysis
Jianhui Du et al.
TRANSLATIONAL CANCER RESEARCH (2021)
Roles of CCL2-CCR2 Axis in the Tumor Microenvironment
Suguru Kadomoto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer
Hiroaki Iwamoto et al.
IN VIVO (2021)
CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway
Hiroaki Yasui et al.
CLINICAL & EXPERIMENTAL METASTASIS (2020)
被撤回的出版物: Endogenous production of C-C motif chemokine ligand 2 by nasopharyngeal carcinoma cells drives radioresistance-associated metastasis (Retracted article. See vol. 558, 2023)
Shan-Shan Guo et al.
CANCER LETTERS (2020)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C. Parker et al.
ANNALS OF ONCOLOGY (2020)
Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer
Noriyuki Hirahara et al.
Oncotarget (2020)
Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?
Hiroaki Iwamoto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20-100 ng/mL
Hiroaki Iwamoto et al.
INTERNATIONAL BRAZ J UROL (2019)
Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells
Kouji Izumi et al.
JOURNAL OF CLINICAL MEDICINE (2019)
CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
Ariunbold Natsagdorj et al.
CANCER SCIENCE (2019)
WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages
Geun Taek Lee et al.
BRITISH JOURNAL OF CANCER (2018)
Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer
Kouji Izumi et al.
ONCOTARGET (2016)
The Relationship Between Prostate-Specific Antigen and TNM Classification or Gleason Score in Prostate Cancer Patients With Low Prostate-Specific Antigen Levels
Kouji Izumi et al.
PROSTATE (2015)
Prognostic role of serum C-reactive protein in esophageal cancer: a systematic review and meta-analysis
Ying Huang et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2015)
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
Igor Tsaur et al.
CANCER RESEARCH AND TREATMENT (2015)
Is C-reactive protein useful in prognostication for colorectal cancer? A systematic review
S. Pathak et al.
COLORECTAL DISEASE (2014)
Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level
Kouji Izumi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Cancer-related inflammation and treatment effectiveness
Connie I. Diakos et al.
LANCET ONCOLOGY (2014)
The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis
Qingfeng Hu et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
CCL2 increases αvβ3 integrin expression and subsequently promotes prostate cancer migration
Tien-Huang Lin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation
Kouji Izumi et al.
EMBO MOLECULAR MEDICINE (2013)
Long-term Outcomes Among Noncuratively Treated Men According to Prostate Cancer Risk Category in a Nationwide, Population-based Study
Jennifer R. Rider et al.
EUROPEAN UROLOGY (2013)
Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone
Peter S. Kirk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes
Jun Panee
CYTOKINE (2012)
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schroder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy
Scott E. Eggener et al.
JOURNAL OF UROLOGY (2011)
Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Matthew R. Cooperberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth
Jian Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
CCL2 Is Induced by Chemotherapy and Protects Prostate Cancer Cells From Docetaxel-Induced Cytotoxicity
David Z. Qian et al.
PROSTATE (2010)
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Satish L. Deshmane et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2009)
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo
Robert D. Loberg et al.
CANCER RESEARCH (2007)
CCL2 is a potent regulator of prostate cancer cell migration and proliferation
Robert D. Loberg et al.
NEOPLASIA (2006)
The chemokine system in neuroinflammation: An update
RM Ransohoff
JOURNAL OF INFECTIOUS DISEASES (2002)
分享论文
